Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.36 |
| ▸ | NPY4R | P50391 | 4/20 | 0.36 |
| ▸ | NPY1R | P25929 | 3/20 | 0.36 |
| ▸ | NPY2R | P49146 | 1/20 | 0.36 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.35 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.34 |
| ▸ | FURIN | P09958 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23789219 | 1.00 | FAP (0.44) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL21477710 | 1.00 | FAP (0.44) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL20841072 | 1.00 | FAP (0.44) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL21897649 | 1.00 | FAP (0.44) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL18937600 | 1.00 | FAP (0.44) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL20889012 | 0.99 | FAP (0.43) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL18911084 | 0.96 | FAP (0.43) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL23353475 | 0.94 | FAP (0.43) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL22643670 | 0.93 | FAP (0.45) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL21861811 | 0.93 | FAP (0.45) | FAPNPY5RNPY4RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. | 2024-07-04 | — | — | US | disclosed |
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220362396-A1 | AMINO-PYRAZINECARBOXAMIDE COMPOUNDS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2022-11-17 | — | — | US | disclosed |
| US-20200246460-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2020-08-06 | — | — | US | disclosed |
| US-20200199247-A1 | ANTIBODY CONJUGATES OF IMMUNE-MODULATORY COMPOUNDS AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2020-06-25 | — | — | US | disclosed |
| US-10640563-B2 | Anti-B7-H3 antibodies and antibody drug conjugates | ABBVIE INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20200031798-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | ARS Pharmaceuticals, Inc. | 2020-01-30 | — | — | US | disclosed |
| US-10442790-B2 | Benzazepine compounds, conjugates, and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-10428045-B2 | Benzazepine compounds, conjugates, and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190142941-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2019-05-16 | — | — | US | disclosed |
| WO-2017214282-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20170355769-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170298139-A1 | COMPOSITIONS OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF | OPI VI - IP HOLDCO LLC | 2017-10-19 | — | — | US | disclosed |
| US-20170182179-A1 | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors | ABBVIE INC. (US) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298139-A1 | COMPOSITIONS OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF | STING1, CGAS, TLR7 | FAP 4182/4885NPY5R 723/4885NPY4R 1756/4885 |
| US-20170182179-A1 | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors | BCL2, BCL2L10, BAX | FAP 3670/4885NPY5R 4345/4885NPY4R 4538/4885 |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | NR3C1, NR3C2, MC2R | FAP 1971/4885NPY5R 546/4885NPY4R 460/4885 |
| US-20200246460-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | FAP 3962/4885NPY5R 4288/4885NPY4R 4524/4885 |
| US-20170355769-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | HRH3, H1-3, CD274 | FAP 3796/4885NPY5R 1908/4885NPY4R 2031/4885 |
| US-10640563-B2 | Anti-B7-H3 antibodies and antibody drug conjugates | HRH3, H1-3, CD274 | FAP 3796/4885NPY5R 1908/4885NPY4R 2031/4885 |
| US-10442790-B2 | Benzazepine compounds, conjugates, and uses thereof | TLR8, TLR3, TLR5 | FAP 3807/4885NPY5R 2567/4885NPY4R 3054/4885 |
| US-20220362396-A1 | AMINO-PYRAZINECARBOXAMIDE COMPOUNDS, CONJUGATES, AND USES THEREOF | TGFBR2, SMAD2, ACVR2A | FAP 35/4885NPY5R 131/4885NPY4R 579/4885 |
| US-10428045-B2 | Benzazepine compounds, conjugates, and uses thereof | TLR8, TLR3, TLR5 | FAP 3807/4885NPY5R 2567/4885NPY4R 3054/4885 |
| US-20200031798-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | TLR8, TLR3, TLR5 | FAP 3807/4885NPY5R 2567/4885NPY4R 3054/4885 |
| US-20200199247-A1 | ANTIBODY CONJUGATES OF IMMUNE-MODULATORY COMPOUNDS AND USES THEREOF | LTK, TGFBR2, TNIK | FAP 1851/4885NPY5R 2476/4885NPY4R 2942/4885 |
| US-20190142941-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | FAP 3962/4885NPY5R 4288/4885NPY4R 4524/4885 |
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | ASGR1, TLR8, HAVCR2 | FAP 3829/4885NPY5R 1889/4885NPY4R 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.